Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study

被引：3
|
作者：
Ficorella, C
Morelli, MF
Ricevuto, E
Cannita, K
Porzio, G
Baldi, PL
Cianci, G
Di Rocco, ZC
Natoli, C
Tinari, N
De Galitiis, F
Calista, F
Marchetti, P
机构：
[1] Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy
[2] Univ Chieti, Dept Oncol & Neurosci, Sect Med Oncol, Chieti, Italy
来源：
BRITISH JOURNAL OF CANCER | 2004年 / 91卷 / 04期
关键词：
breast cancer; docetaxel; 5-fluorouracil;
D O I：
10.1038/sj.bjc.6601971
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A dose-finding study was undertaken to determine the maximum-tolerated dose, and the recommended dose of docetaxel in combination with 12-h timed (22:00-10:00) flat infusion of 5-fluorouracil (5-FU) in metastatic breast cancer patients. This schedule seems to reduce the occurrence of stomatitis of the docetaxel and infusional 5-FU regimen.
引用
收藏
页码：618 / 620
页数：3
相关论文
共 50 条
  • [1] Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study
    C Ficorella
    M F Morelli
    E Ricevuto
    K Cannita
    G Porzio
    P Lanfiuti Baldi
    G Cianci
    ZC Di Rocco
    C Natoli
    N Tinari
    F De Galitiis
    F Calista
    P Marchetti
    British Journal of Cancer, 2004, 91 : 618 - 620
  • [2] Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study
    Ficorella, C
    Ricevuto, E
    Morelli, MF
    Morese, R
    Cannita, K
    Cianci, G
    Porzio, G
    Di Rocco, ZC
    De Galitiis, F
    De Tursi, M
    Tinari, N
    Iacobelli, S
    Marchetti, P
    ONCOLOGY REPORTS, 2006, 15 (05) : 1345 - 1350
  • [3] Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: A dose-finding study for ambulatory patients with breast cancer
    Hietanen, P
    Teerenhovi, L
    Joensuu, H
    ONCOLOGY, 1999, 56 (02) : 103 - 109
  • [4] Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: a phase I, dose-finding study
    Lortholary, A
    Maillard, P
    Delva, R
    Boisdron-Celle, M
    Perard, D
    Vernillet, L
    Besenval, M
    Gamelin, E
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (14) : 1773 - 1780
  • [5] Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen
    André, T
    Louvet, C
    Raymond, E
    Tournigand, C
    de Gramont, A
    ANNALS OF ONCOLOGY, 1998, 9 (11) : 1251 - 1253
  • [6] Pilot study of continuous low-dose 5-fluorouracil and cisplatin (FP regimen) for the treatment of metastatic breast cancer
    Yamada Y.
    Aiba K.
    Horikosi N.
    Hanai M.
    Uno S.
    Osawa H.
    Mizunuma N.
    Takahashi S.
    Ito Y.
    International Journal of Clinical Oncology, 2000, 5 (1) : 18 - 21
  • [7] Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis
    Li, Bo
    Chen, Lian
    Luo, Hong-Liang
    Yi, Feng-Ming
    Wei, Yi-Ping
    Zhang, Wen-Xiong
    WORLD JOURNAL OF CLINICAL CASES, 2019, 7 (05) : 600 - 615
  • [8] Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin,cisplatin, and 5-fluorouracil regimen for advanced gastric cancer:A systematic review and meta-analysis
    Bo Li
    Lian Chen
    Hong-Liang Luo
    Feng-Ming Yi
    Yi-Ping Wei
    Wen-Xiong Zhang
    World Journal of Clinical Cases, 2019, (05) : 600 - 615
  • [9] Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure
    Bonneterre, J
    Roché, H
    Monnier, A
    Guastalla, JP
    Namer, M
    Fargeot, P
    Assadourian, S
    BRITISH JOURNAL OF CANCER, 2002, 87 (11) : 1210 - 1215
  • [10] Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure
    J Bonneterre
    H Roché
    A Monnier
    J P Guastalla
    M Namer
    P Fargeot
    S Assadourian
    British Journal of Cancer, 2002, 87 : 1210 - 1215
12345